Pharma's Q1 to benefit from higher prices

Most major U.S. drugmakers' first-quarter results are likely to benefit from higher prices as the industry continues efforts to bolster product pipelines ahead of the expiration of patent protection on some key drugs over the next few years, Dow Jones says. Report